Veterinary medical education for modern food systems: past, present, and brainstorming a future

Concepts presented here were derived from breakout sessions constituted by the 90 attendees of the Veterinary Medical Education for Modern Food Systems symposium, held in Kansas City, Missouri, USA, in October 2005. The attendees were food-animal educators, veterinary faculty, college deans and administrators, and veterinarians employed in government, industry, and private practice. Discussions at these breakout sessions focused on four primary areas: (1) determining the data needed to document the current demand for food-supply veterinarians (FSVs); (2) defining the information/skills/abilities needed within veterinary school curricula to address the current demands on FSVs; (3) outlining pre-DVM educational requirements needed to support FSVs; and (4) considering the role of post-DVM programs in meeting the demand for FSVs.     

犬的过去、现在和未来

从古罗马开始，人们已根据犬的技能进行分类。最初，把它们分为牧畜犬、猎犬和家庭犬。亚里士多德记录了7类犬，但没有记录灵猩，当时它还生活在埃及。到了18世纪，布丰（法国博物学家，古生物学创始人）试图根据犬的耳型来分类，把它们分为直耳、塌耳和半直立耳等30个品种。然而，居维叶（法国博物学家，古生物学创立者）建议根据犬颅骨形状，把犬分为猎犬、獒和獚。1885年，     

Brucellosis vaccines: past,present and future

The first effective Brucella vaccine was based on live Brucella abortus strain 19, a laboratory-derived strain attenuated by an unknown process during subculture. This induces reasonable protection against B. abortus, but at the expense of persistent serological responses. A similar problem occurs with the B. melitensis Rev.1 strain that is still the most effective vaccine against caprine and ovine brucellosis. Vaccines based on killed cells of virulent strains administered with adjuvant induced significant protection but also unacceptable levels of antibodies interfering with diagnostic tests. Attempts were made to circumvent this problem by using a live rough strain B. abortus 45/20, but this reverted to virulence in vivo. Use of killed cells of this strain in adjuvant met with moderate success but batch to batch variation in reactogenicity and agglutinogenicity limited application. This problem has been overcome by the development of the rifampicin-resistant mutant B. abortus RB51 strain. This strain has proved safe and effective in the field against bovine brucellosis and exhibits negligible interference with diagnostic serology. Attempts are being made to develop defined rough mutant vaccine strains that would be more effective against B. melitensis and B. suis. Various studies have examined cell-free native and recombinant proteins as candidate protective antigens, with or without adjuvants. Limited success has been obtained with these or with DNA vaccines encoding known protective antigens in experimental models and further work is indicated.     

Foot-and-mouth disease: past,present and future

Foot-and-mouth disease (FMD) is a highly contagious disease of cloven-hoofed animals including cattle, pigs, sheep and many wildlife species. It can cause enormous economic losses when incursions occur into countries which are normally disease free. In addition, it has long-term effects within countries where the disease is endemic due to reduced animal productivity and the restrictions on international trade in animal products. The disease is caused by infection with foot-and-mouth disease virus (FMDV), a picornavirus. Seven different serotypes (and numerous variants) of FMDV have been identified. Some serotypes have a restricted geographical distribution, e.g. Asia-1, whereas others, notably serotype O, occur in many different regions. There is no cross-protection between serotypes and sometimes protection conferred by vaccines even of the same serotype can be limited. Thus it is important to characterize the viruses that are circulating if vaccination is being used for disease control. This review describes current methods for the detection and characterization of FMDVs. Sequence information is increasingly being used for identifying the source of outbreaks. In addition such information can be used to understand antigenic change within virus strains. The challenges and opportunities for improving the control of the disease within endemic settings, with a focus on Eurasia, are discussed, including the role of the FAO/EuFMD/OIE Progressive Control Pathway. Better control of the disease in endemic areas reduces the risk of incursions into disease-free regions.     

Veterinary education,present and future needs

Extract

It is a very great pleasure to be here today to deliver the Jubilee Veterinary Oration at this veterinary school, for whose staff and graduates I have a very great affection. I feel some empathy with Marc Antony whose words so well reflect my own feeling about my capacity for the task.     

Equine viral vaccines: the past, present and future

The increasing international movement of horses combined with the relaxation of veterinary regulations has resulted in an increased incidence of equine infectious diseases. Vaccination, along with management measures, has become the primary method for the effective control of these diseases. Traditionally modified live and inactivated vaccines have been used and these vaccines have proven to be very successful in preventing disease. However, there are a number of equine infectious diseases for which conventional technology has shown its limitations. The advent of recombinant technology has stimulated the development of second generation vaccines, including gene deleted mutants, live vectored vaccines and DNA vaccines. These vaccines have in common that protective antigens are endogenously processed and presented along the molecules of the MHC I and MHC II complex, resulting in the stimulation of both humoral and cell-mediated immune responses similar to natural infection. The present paper provides a review of the vaccines being employed today against the most important equine viral diseases followed by a summary of new developments that are expected to bring improved vaccines to the market in the foreseeable future.     

Sulfonamide residues in pork: past, present, and future

The Food Safety and Inspection Service (FSIS) of the U. S. Department of Agriculture (USDA) has been involved for a number of years with the problem of sulfonamide residues in pork. In the 1970s, concern was raised regarding the use of sulfonamides when food safety criteria used for premarketing approval of new animal drugs and the safety data base for sulfonamides were found to be inadequate. Regulatory analytical methods for monitoring sulfonamides were developed and put to use by FSIS. With educational efforts by government and industry, by 1980 it was thought that the problem was being solved. In the 1980s, however, the sulfonamide violation rate began to increase; the USDA strengthened its educational programs, developed a rapid test for sulfonamides and pursued regulatory initiatives. By 1987 sulfonamide violations in liver tissue (i.e., greater than .1 ppm) had declined to 3.8%; however, new toxicological information associating sulfamethazine with the development of follicular cell adenomas of the thyroid gland in rats and mice led the FSIS to begin an enhanced sulfamethazine control program in the spring of 1988. The FSIS believes that production quality assurance is the key to prevention. The Agency's initiatives toward this end are designed both to encourage industry accountability and to provide disincentives for violators. The current approaches to the sulfonamide problem hold the clear promise of a satisfactory solution.     

Mesenchymal stromal cells: past, present, and future

Adult mesenchymal stromal cells are plastic-adherent cells that are self-renewing and have the capacity to differentiate into various tissue specific lineages. Stromal cells were initially discovered over 100 years ago and substantial insight into stromal cell identification, isolation, characterization, and differentiation has been made, including efforts to elucidate the factors involved in stromal cell differentiation. Stromal cells have immune privilege and thus are attractive candidates for tissue engineering and regenerative medicine applications. Positive results from a number of recent investigations support the use of adult mesenchymal stromal cells for clinical application. This review article provides a brief overview of past, present, and future stromal cell technology.